Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.58 USD | +6.47% | +7.71% | +23.77% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.77% | 7.78B | B | ||
-18.71% | 16.53B | B+ | ||
-10.94% | 15.21B | A- | ||
+1.80% | 12.44B | B | ||
0.00% | 11.22B | B+ | ||
+11.44% | 10.75B | B+ | ||
+7.41% | 8.39B | A- | ||
+22.00% | 7.22B | D | ||
+2.79% | 4.64B | - | ||
+37.74% | 4.32B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Encompass Health Corporation - Nyse
- Ratings Encompass Health Corporation